Dubai:Medcare Royal Speciality Hospital in Al Qusais has become one of the first centres outside the United States to offer a newly licensed intrathecal gene therapy for Spinal Muscular Atrophy (SMA), significantly expanding treatment options for patients over two years of age.
The breakthrough therapy removes previous age and weight restrictions, allowing children, teenagers and adults with SMA to access gene therapy for the first time. The treatment addresses the root genetic cause of the disease by delivering a functional copy of the missing SMN1 gene, offering a one-time, potentially life-changing intervention.
Dr. Shanila Laiju, Group CEO of Medcare Hospitals & Medical Centres, said the development brings renewed hope to families who were previously ineligible for gene therapy. Consultant Paediatric Neurologist Dr. Vivek Mundada described it as a “paradigm shift” that helps older patients preserve mobility, independence and breathing function.
Since 2020, Medcare has treated 180 children with SMA, including international patients, reinforcing the UAE’s growing role as a global hub for advanced genetic and paediatric care
